Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the novel terminology encompassing liver disease associated with metabolic dysfunction, replacing the previous terminology of non-alcoholic fatty liver disease (NAFLD). This disease is strongly associated with metabolic disorders su...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Livers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-4389/5/1/4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850091237681397760 |
|---|---|
| author | Thaninee Prasoppokakorn |
| author_facet | Thaninee Prasoppokakorn |
| author_sort | Thaninee Prasoppokakorn |
| collection | DOAJ |
| description | Metabolic dysfunction-associated steatotic liver disease (MASLD) is the novel terminology encompassing liver disease associated with metabolic dysfunction, replacing the previous terminology of non-alcoholic fatty liver disease (NAFLD). This disease is strongly associated with metabolic disorders such as obesity, type 2 diabetes, and dyslipidemia. MASLD and dyslipidemia are deeply interconnected, driven by shared pathophysiological mechanisms. Emerging evidence suggests that statins, a class of lipid-lowering medications, may have beneficial effects on MASLD beyond their primary role in reducing cholesterol levels through several mechanisms, including anti-inflammatory, antioxidant, anti-fibrosis, and immunomodulatory effects. This review aims to summarize the efficacy of statins in the management of MASLD and provide insights into their potential mechanisms of action. It discusses the pathophysiology of MASLD and the role of statins in targeting key aspects of the disease. Additionally, the review examines the clinical evidence supporting the use of different statins in MASLD treatment and highlights their specific effects on liver enzymes, inflammation, and fibrosis. Furthermore, an algorithm for statin therapy in MASLD is proposed based on the current knowledge and available evidence. |
| format | Article |
| id | doaj-art-f48b326464fa4462be217d7cd9c054e8 |
| institution | DOAJ |
| issn | 2673-4389 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Livers |
| spelling | doaj-art-f48b326464fa4462be217d7cd9c054e82025-08-20T02:42:25ZengMDPI AGLivers2673-43892025-01-0151410.3390/livers5010004Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Thaninee Prasoppokakorn0Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok 10330, ThailandMetabolic dysfunction-associated steatotic liver disease (MASLD) is the novel terminology encompassing liver disease associated with metabolic dysfunction, replacing the previous terminology of non-alcoholic fatty liver disease (NAFLD). This disease is strongly associated with metabolic disorders such as obesity, type 2 diabetes, and dyslipidemia. MASLD and dyslipidemia are deeply interconnected, driven by shared pathophysiological mechanisms. Emerging evidence suggests that statins, a class of lipid-lowering medications, may have beneficial effects on MASLD beyond their primary role in reducing cholesterol levels through several mechanisms, including anti-inflammatory, antioxidant, anti-fibrosis, and immunomodulatory effects. This review aims to summarize the efficacy of statins in the management of MASLD and provide insights into their potential mechanisms of action. It discusses the pathophysiology of MASLD and the role of statins in targeting key aspects of the disease. Additionally, the review examines the clinical evidence supporting the use of different statins in MASLD treatment and highlights their specific effects on liver enzymes, inflammation, and fibrosis. Furthermore, an algorithm for statin therapy in MASLD is proposed based on the current knowledge and available evidence.https://www.mdpi.com/2673-4389/5/1/4statinsteatotic liver diseasemetabolic dysfunctionMASLD |
| spellingShingle | Thaninee Prasoppokakorn Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Livers statin steatotic liver disease metabolic dysfunction MASLD |
| title | Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) |
| title_full | Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) |
| title_fullStr | Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) |
| title_full_unstemmed | Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) |
| title_short | Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) |
| title_sort | applicability of statins in metabolic dysfunction associated steatotic liver disease masld |
| topic | statin steatotic liver disease metabolic dysfunction MASLD |
| url | https://www.mdpi.com/2673-4389/5/1/4 |
| work_keys_str_mv | AT thanineeprasoppokakorn applicabilityofstatinsinmetabolicdysfunctionassociatedsteatoticliverdiseasemasld |